Validation of the usefulness of artificial neural networks for risk prediction of adverse drug reactions used for individual patients in clinical practice.

Journal: PloS one
PMID:

Abstract

Artificial neural networks are the main tools for data mining and were inspired by the human brain and nervous system. Studies have demonstrated their usefulness in medicine. However, no studies have used artificial neural networks for the prediction of adverse drug reactions. We aimed to validate the usefulness of artificial neural networks for the prediction of adverse drug reactions and focused on vancomycin -induced nephrotoxicity. For constructing an artificial neural network, a multilayer perceptron algorithm was employed. A 10-fold cross validation method was adopted for evaluating the resultant artificial neural network. In total, 1141 patients who received vancomycin at Hokkaido University Hospital from November 2011 to February 2019 were enrolled. Among these patients, 179 (15.7%) developed vancomycin -induced nephrotoxicity. The top three risk factors of vancomycin -induced nephrotoxicity which are relatively important in the artificial neural networks were average vancomycin trough concentration ≥ 13.0 mg/L and concomitant use of piperacillin-tazobactam and vasopressor drugs. The predictive accuracy of the artificial neural network was 86.3% and that of the multiple logistic regression model (conventional statistical method) was 85.1%. Moreover, area under the receiver operating characteristic curve (AUROC) of the artificial neural network was 0.83. In the 10-fold cross-validation, the accuracy obtained was 86.0% and AUROC was 0.82. The artificial neural network model predicting the vancomycin -induced nephrotoxicity showed good predictive performance. This appears to be the first report of the usefulness of artificial neural networks for an adverse drug reactions risk prediction model.

Authors

  • Shungo Imai
    Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
  • Yoh Takekuma
    Department of Pharmacy, Hokkaido University Hospital, Sapporo, Japan.
  • Hitoshi Kashiwagi
    Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
  • Takayuki Miyai
    Graduate School of Life Science, Hokkaido University, Sapporo, Japan.
  • Masaki Kobayashi
    Mathematical Science Center, University of Yamanashi, Takeda 4-3-11, Kofu, Yamanashi 400-8511, Japan.
  • Ken Iseki
    Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
  • Mitsuru Sugawara
    Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.